Hypertension: Management perspectives

Expert Opinion on Pharmacotherapy

Volumn 13, Issue 14, 2012, Pages 1999-2003

  Borghi, Claudio ^a   Cicero, Arrigo F G ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Blood pressure; Diagnosis; Hypertension; Management; Perspectives; Therapeutics

Indexed keywords

ALDOSTERONE SYNTHASE INHIBITOR; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIHYDROPYRIDINE DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN RECEPTOR ANTAGONIST; NEPRILYSIN INHIBITOR; PRORENIN RECEPTOR BLOCKER; RECOMBINANT RENALASE; RENIN RECEPTOR BLOCKER; UNCLASSIFIED DRUG;

AEROBIC EXERCISE; ANGIONEUROTIC EDEMA; ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE REGULATION; DRUG EFFICACY; DRUG SAFETY; EARLY DIAGNOSIS; GENETIC RISK; HUMAN; HYPERTENSION; LIFESTYLE MODIFICATION; PERIPHERAL EDEMA; PERSONALIZED MEDICINE; RELAXATION TRAINING; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK ASSESSMENT; RISK REDUCTION; SIDE EFFECT; SODIUM RESTRICTION; SODIUM RETENTION; TREATMENT INDICATION; WATER RETENTION;

ANTIHYPERTENSIVE AGENTS; DISEASE MANAGEMENT; HUMANS; HYPERTENSION;

EID: 84866234220     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2012.708733     Document Type: Review

References (40)

1. Harmon L, Chilton RJ, Spellman C. Reducing cardiovascular events and end-organ damage in patients with hypertension: new considerations. Postgrad Med 2011;123(2):7-17.
2. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009;338:b1665
3. Harmon L, Chilton RJ, Spellman C. Reducing cardiovascular events and end-organ damage in patients with hypertension: new considerations. Postgrad Med 2011;123(2):7-17
4. Palmieri L, Bennett K, Giampaoli S, et al. Explaining the decrease in coronary heart disease mortality in Italy between 1980 and 2000. Am J Public Health 2010;100(4):684-92
5. Young F, Capewell S, Ford ES, et al. Coronary mortality declines in the U.S. between 1980 and 2000 quantifying the contributions from primary and secondary prevention. Am J Prev Med 2010;39(3):228-34
6. Egan BM, Zhao Y, Axon RN. US trends in prevalence, awareness, treatment, and control of hypertension, 1988-2008. JAMA 2010;303(20):2043-50
7. Banegas JR, López-García E, Dallongeville J, et al. Achievement of treatment goals for primary prevention of cardiovascular disease in clinical practice across Europe: the EURIKA study. Eur Heart J 2011;32(17):2143-52
8. Flack JM. Epidemiology and unmet needs in hypertension. J Manag Care Pharm 2007;13(8 Suppl B):2-8
9. International Consortium for Blood Pressure Genome-Wide Association Studies. Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature 2011;478(7367):103-9
10. Campbell CY, Blumenthal RS. Pharmacogenetics of antihypertensive response. Hypertension 2012;59(6):1094-6
11. Mancia G, De Backer G, Dominiczak A, et al. ESH-ESC Task Force on the Management of Arterial Hypertension. 2007 ESH-ESC practice guidelines for the management of arterial hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension. J Hypertens 2007;25(9):1751-62 (Pubitemid 47356612)
12. Al-Solaiman Y, Jesri A, Mountford WK, et al. DASH lowers blood pressure in obese hypertensives beyond potassium, magnesium and fibre. J Hum Hypertens 2010;24(4):237-46
13. Dickinson HO, Mason JM, Nicolson DJ, et al. Lifestyle interventions to reduce raised blood pressure: A systematic review of randomized controlled trials. J Hypertens 2006;24(2):215-33
14. Weintraub WS, Daniels SR, Burke LE, et al. American Heart Association Advocacy Coordinating Committee; Council on Cardiovascular Disease in the Young; Council on the Kidney in Cardiovascular Disease; Council on Epidemiology and Prevention; Council on Cardiovascular Nursing; Council on Arteriosclerosis; Thrombosis and Vascular Biology; Council on Clinical Cardiology, and Stroke Council. Value of primordial and primary prevention for cardiovascular disease: A policy statement from the American Heart Association. Circulation 2011;124(8):967-90
15. Campbell DJ. Vaccination against high blood pressure. Curr Pharm Des 2012; 18(7):1005-10
16. Borghi C, Laghi L, Cicero AFG. From lipid disorders to high blood pressure: is it possible to extend the paradigm of CV prevention? Cardiol Clin Pract 2010; 2(3):109-12
17. Cicero AFG, D'Addato S, Veronesi M, et al. for the Brisighella Heart Study Group. Relationship between blood pressure, cholesterolemia and serum apolipoprotein B in a large population sample: the Brisighella Heart Study. J Hypertens 2012;30(3):492-6
18. Sesso HD, Buring JE, Chown MJ, et al. A prospective study of plasma lipid levels and hypertension in women. Arch Intern Med 2005;165(20): 2420-7 (Pubitemid 41640856)
19. Halperin RO, Sesso HD, Ma J, et al. Dyslipidemia and the risk of incident hypertension in men. Hypertension 2006;47(1):45-50 (Pubitemid 43177814)
20. Elton TS, Martin MM. Angiotensin II type 1 receptor gene regulation: transcriptional and posttranscriptional mechanisms. Hypertension 2007;49(5):953-61 (Pubitemid 351664299)
21. Ekelund LG. Lowering lipids and the genesis of hypertension. Drugs 1988;36(Suppl 3):21
22. Borghi C, Dormi A, Veronesi M, et al. Brisighella Heart Study Working Party. Association between different lipidlowering treatment strategies and blood pressure control in the Brisighella Heart Study. Am Heart J 2004;148(2):285-92 (Pubitemid 39092793)
23. Ford ES. Trends in mortality from all causes and cardiovascular disease among hypertensive and nonhypertensive adults in the United States. Circulation 2011;123(16):1737-44
24. Rothwell PM, Howard SC, Dolan E, et al. Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension. Lancet 2010;375(9718): 895-905
25. Safar ME, Blacher J, Jankowski P. Arterial stiffness, pulse pressure, and cardiovascular disease-is it possible to break the vicious circle? Atherosclerosis 2011;218(2):263-71
26. Laurent S, Cockcroft J, Van Bortel L, et al. European Network for Non-invasive Investigation of Large Arteries. Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J 2006;27(21):2588-605 (Pubitemid 44627304)
27. Williams B, Lacy PS, Thom SM, et al. CAFE Investigators; Anglo-Scandinavian Cardiac Outcomes Trial Investigators; CAFE Steering Committee and Writing Committee. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 2006;113(9):1213-25
28. Mancia G, Schumacher H, Redon J, et al. Blood pressure targets recommended by guidelines and incidence of cardiovascular and renal events in the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial (ONTARGET). Circulation 2011;124(16):1727-36
29. Egan BM, Zhao Y, Axon RN, et al. Uncontrolled and apparent treatment resistant hypertension in the United States, 1988 to 2008. Circulation 2011;124(9):1046-58
30. Packer M, Califf RM, Konstam MA, et al. Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat vs. Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). Circulation 2009;106:920-6
31. Ruilope LM, Dukat A, Bohm M, et al. Blood pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: A randomised, double-blind, placebo-controlled, active comparator study. Lancet 2010;375:1255-66
32. Arhancet GB, Woodard SS, Dietz JD, et al. Stereochemical requirements for the mineralocorticoid receptor antagonist activity of dihydropyridines. J Med Chem 2010;53:4300-4
33. Isaka T, Ikeda K, Takada Y, et al. Azelnidipine inhibits aldosterone synthesis and secretion in human adrenocortical cell line NCI-H295R. Eur J Pharmacol 2009;605:49-52
34. Lazich I, Bakris GL. Endothelin antagonism in patients with resistant hypertension and hypertension nephropathy. Contrib Nephrol 2011;172:223-34
35. Paulis L, Steckelings UM, Unger T. Key advances in antihypertensive treatment. Nat Rev Cardiol 2012; Epub ahead of print
36. Unger T, Paulis L, Sica DA. Therapeutic perspectives in hypertension: novel means for renin-angiotensin-aldosterone system modulation and emerging device-based approaches. Eur Heart J 2011;32(22):2739-47
37. Symplicity HTN-1 Investigators. Catheter-based renal sympathetic denervation for resistant hypertension: durability of blood pressure reduction out to 24 months. Hypertension 2011;57(5):911-17
38. Symplicity HTN-2 Investigators. Esler MD, Krum H, Sobotka PA, et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): A randomised controlled trial. Lancet 2010;376(9756):1903-9
39. Papademetriou V, Doumas M, Faselis C, et al. Carotid baroreceptor stimulation for the treatment of resistant hypertension. Int J Hypertens 2011;2011:964394
40. Cohen JD. Hypertension epidemiology and economic burden: refining risk assessment to lower costs. Manag Care 2009;18(10):51-8